-
Product Insights
NewPreora Healthcare Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Preora Healthcare Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Preora Healthcare Inc is a private medical device company focused on developing technology for the early detection and treatment of cancer through its proprietary Partial Wave Spectroscopy (PWS) Nanocytologyâ„¢ platform, which is licensed exclusively by Preora through ISO 13485-certified NanoCytomics, LLC and Northwestern University. The platform enables the study of cells at the nanoscale, resulting in an enhanced understanding...
-
Product Insights
NewStarpharma Holdings Ltd Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Starpharma Holdings Ltd Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Starpharma Holdings Ltd (Starpharma) is a biotechnology company, which researches, develops and manufactures dendrimer products for pharmaceutical, life sciences and other applications. Dendrimers are synthetic nanoscale polymers with pharmaceutical and medical uses. The company’s development programs include its DEP drug delivery, which is built around dendrimers and VivaGel portfolio. Its flagship product candidate, VivaGel, is a gel-based formulation for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RiMO-301 in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RiMO-301 in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RiMO-301 in Recurrent Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Quaratusugene Ozeplasmid in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Quaratusugene Ozeplasmid in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Quaratusugene Ozeplasmid in Small-Cell Lung Cancer Drug Details: GPX-001 in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Quaratusugene Ozeplasmid in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Quaratusugene Ozeplasmid in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Quaratusugene Ozeplasmid in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RiMO-301 in Recurrent Head And Neck Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RiMO-301 in Recurrent Head And Neck Squamous Cell Carcinoma Drug Details: RiMO-301 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CPI-100 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CPI-100 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CPI-100 in Solid Tumor Drug Details: CPI-100 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RiMO-301 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RiMO-301 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RiMO-301 in Recurrent Head And Neck Cancer...
-
Company Profile
Starpharma Holdings Ltd – Company Profile
Starpharma Holdings Ltd (Starpharma) is a biotechnology company, which researches, develops and manufactures dendrimer products for pharmaceutical, life sciences and other applications. Dendrimers are synthetic nanoscale polymers with pharmaceutical and medical uses. The company’s development programs include its DEP drug delivery, which is built around dendrimers and VivaGel portfolio. Its flagship product candidate, VivaGel, is a gel-based formulation for the treatment and prevention of bacterial vaginosis (BV) and it is also used as a vaginal microbicide to prevent sexually transmitted...
Add to Basket